
Contents

<i>Preface</i>	v
<i>Acknowledgments</i>	vii
<i>Contributors</i>	xiii

PART I BACKGROUND

1 The Path to Oncology Drug Target Validation: An Industry Perspective	3
<i>Marta Cortés-Cros, Tobias Schmelzle, Volker M. Stucke, and Francesco Hofmann</i>	

PART II DNA AS A TOOL TO MODULATE DRUG TARGETS

2 Identification of Aptamers as Specific Binders and Modulators of Cell-Surface Receptor Activity.	17
<i>Henning Ulrich and Carsten Wrenger</i>	
3 The Design and Structure–Functional Properties of DNA-Based Immunomodulatory Sequences	41
<i>Nikolai V. Kuznetsov</i>	

PART III RNA INTERFERENCE: FROM DESIGN TO DATA ANALYSIS

4 siRNA Design Principles and Off-Target Effects	59
<i>Sebastian Petri and Gunter Meister</i>	
5 Western Blot Evaluation of siRNA Delivery by pH-Responsive Peptides	73
<i>Wanling Liang, A. James Mason, and Jenny K.W. Lam</i>	
6 High-Throughput RNAi Screening for the Identification of Novel Targets	89
<i>Meredith C. Henderson and David O. Azorsa</i>	
7 Integration of RNAi and Small Molecule Screens to Identify Targets for Drug Development	97
<i>Konstantinos Drosopoulos and Spiros Linardopoulos</i>	
8 CellProfiler and KNIME: Open Source Tools for High Content Screening	105
<i>Martin Stöter, Antje Niederlein, Rico Barsacchi, Felix Meyenhofer, Holger Brandl, and Marc Bickle</i>	
9 PARP Inhibition as a Prototype for Synthetic Lethal Screens	123
<i>Xuesong Liu</i>	

PART IV PROTEIN-FOCUSED TECHNOLOGIES

10	Structure-Based Target Druggability Assessment	141
	<i>Jean-Yves Trosset and Nicolas Vodovar</i>	
11	Validating Pharmacological Disruption of Protein-Protein Interactions by Acceptor Photobleaching FRET Imaging	165
	<i>Janos Roszik, Gábor Tóth, János Szöllösi, and György Vereb</i>	
12	Systematic Analysis of Complex Signal Transduction Pathways Using Protein Fragment Complementation Assays	179
	<i>Thomas I. Koblizek, Ann Siehoff, and Anthony Pitt</i>	
13	Reverse Phase Protein Microarrays and Their Utility in Drug Development	187
	<i>Maria Isabella Sereni, Mariaelena Pierobon, Roberto Angioli, Emanuel F. Petricoin III, and Mitchell J. Frederick</i>	

PART V INNOVATIVE CELL CULTURE TECHNIQUES TO MIMIC TISSUE
MICROENVIRONMENTS

14	A Cell Culture System That Mimics Chronic Lymphocytic Leukemia Cells Microenvironment for Drug Screening and Characterization	217
	<i>Alessandro Naroni, Michael O'Dwyer, and Corrado Santocanale</i>	
15	Two-Dimensional vs. Three-Dimensional In Vitro Tumor Migration and Invasion Assays.	227
	<i>Miriam Zimmermann, Carol Box, and Suzanne A. Eccles</i>	
16	Tumor Spheroid-Based Migration Assays for Evaluation of Therapeutic Agents.	253
	<i>Maria Vinci, Carol Box, Miriam Zimmermann, and Suzanne A. Eccles</i>	
17	The Neurosphere Assay Applied to Neural Stem Cells and Cancer Stem Cells	267
	<i>Rossella Galli</i>	

PART VI GENETICALLY ENGINEERED ANIMAL MODELS TO STUDY GENE
FUNCTIONS

18	Genetically Engineered Animal Models for In Vivo Target Identification and Validation in Oncology	281
	<i>Gemma Texidó</i>	
19	Target Validation in Mice by Constitutive and Conditional RNAi	307
	<i>Aljoscha Kleinhammer, Wolfgang Wurst, and Ralf Kühn</i>	
20	In Vivo Target Validation by Inducible RNAi in Human Xenograft Mouse Models	325
	<i>Marco Mazzeletti and Gemma Texidó</i>	

PART VII TRANSLATIONAL METHODS TO VALIDATE BIOMARKERS

21 Bright-Field In Situ Hybridization Methods to Discover Gene Amplifications and Rearrangements in Clinical Samples 341
Hiroaki Nitta and Thomas M. Grogan

22 Combined MicroRNA In Situ Hybridization and Immunohistochemical Detection of Protein Markers 353
Boye Schnack Nielsen and Kim Holmstrøm

Index 367